The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First‐Line Hypomethylating Agents Fail

BACKGROUND. Although hypomethylating agents (HMAs) are effective and approved therapies for patients with myelodysplastic syndromes (MDS), many patients do not benefit from treatment, and nearly all ultimately stop responding to HMAs. The incidence and cost burden of HMA failure are unknown yet need...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Cogle, Christopher R., Kurtin, Sandra E., Bentley, Tanya G. K., Broder, Michael S., Chang, Eunice, Megaffin, Scott, Fruchtman, Steven, Petrone, Michael E., Mukherjee, Sudipto
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Academia‐Pharma Intersect
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5388372/
https://ncbi.nlm.nih.gov/pubmed/28283585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0211
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados